Navigation Links
Emissary Capital Group Initiates Coverage on Sinobiopharma
Date:9/21/2009

NEW YORK, Sept. 21 /PRNewswire/ -- Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) with a Buy rating and target price of $1.00-$1.25. Jiangsu, China-based SNBP, known domestically as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products. The company focuses primarily on the development of anesthesia-assisted agents as well as antibiotics for penicillin-allergic patients and cardiovascular-related products related to high blood pressure (commercial in October 2009). KuTai, SNBP's flagship product is a first-to-market Cisatracurium Besylate injectable that serves as a low cost skeletal muscle relaxant used during pre-surgical and surgical procedures. The company holds five patents in Chiral Pharmaceutical Ingredient Synthesis and Purification, and Molecular Packaging Formulation (see proprietary technology section) and has the longer-term ability to expand both the breadth of its product line and market share through R&D partnerships with Cornell University, Nanjing University, China Pharmaceutical University, and Nanjing Medical University.

About Emissary Capital Group

Emissary Capital Group, Inc. is a New York City-based company that provides strategic consulting and research services to emerging growth companies primarily based in India and China. The firm provides a diversified array of services to small and medium sized private companies, generally defined as those with annual revenues under $200 million, in order to assist them to become publicly traded companies in the U.S. For more information, please visit www.emissarycapital.com

    Contact:
    Albert Lee
    Emissary Capital Group, LLC
    1-212-297-6218


'/>"/>
SOURCE Emissary Capital Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
4. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
5. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
7. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
8. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
9. Altheus Therapeutics Secures $3.6 Million in Venture Capital
10. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... and paralysis, today announced that it has submitted a 510(k) to the FDA, ... that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission ...
(Date:1/18/2017)... OF PRUSSIA, PA (PRWEB) , ... January 18, ... ... disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives ... AstraZeneca in engaging panel discussions to examine vital clinical research issues such as ...
(Date:1/18/2017)... Francisco, CA (PRWEB) , ... January 18, 2017 ... ... to report the publishing of the latest paper by its Science Editor, Dr. ... Microbiology (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
Breaking Biology Technology:
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
Breaking Biology News(10 mins):